Projects funded by the NCN

Information on the principal investigator and host institution

Information of the project and the call

Keywords

Equipment

Delete all

Next generation in vitro experimental model of melanoma for pharmacological studies

2014/15/B/NZ7/00947

Keywords:

melanoma genetic profile MAPK pathway inhibitors targeted tharapy vemurafenib trametinib

Descriptors:

  • NZ7_14:
  • NZ7_16:

Panel:

NZ7 - Diagnostic tools, therapies and public health: public health, epidemiology, environmental health risks and occupational medicine, medical ethics, drug discovery and therapies, pharmacology

Host institution :

Uniwersytet Medyczny w Łodzi, Wydział Lekarski

woj. łódzkie

Other projects carried out by the institution 

Principal investigator (from the host institution):

prof. Małgorzata Ewa Czyż 

Number of co-investigators in the project: 6

Call: OPUS 8 - announced on 2014-09-15

Amount awarded: 1 398 040 PLN

Project start date (Y-m-d): 2015-07-16

Project end date (Y-m-d): 2019-07-15

Project duration:: 48 months (the same as in the proposal)

Project status: Project settled

Equipment purchased [PL]

  1. Platforma do rejestrowania obrazu komórek w czasie rzeczywistym zawierająca całkowicie zautomatyzowany mikroskop fluorescencyjny z oprogramowaniem (480 000 PLN)
  2. Inkubator do howowli komórkowych (34 000 PLN)
  3. Wysokopojemny zasobnik dla azotu (25 000 PLN)

Information in the final report

  • Publication in academic press/journals (18)
  1. miRNAs in Melanoma: Tumor Suppressors and Oncogenes with Prognostic Potential.
    Authors:
    Wozniak M, Mielczarek A, Czyz M.
    Academic press:
    Current Medicinal Chemistry (rok: 2016, tom: 23 (28), strony: 3136-3153), Wydawca: Bentham Science Publishers
    Status:
    Published
  2. Fibroblast Growth Factor Receptor Signaling in Skin Cancers
    Authors:
    Czyz M
    Academic press:
    Cells (rok: 2019, tom: 8, strony: E540), Wydawca: MDPI
    Status:
    Published
    DOI:
    10.3390/cells8060540 - link to the publication
  3. Role of miRNAs in Melanoma Metastasis
    Authors:
    Anna Gajos-Michniewicz, Małgorzata Czyż
    Academic press:
    Cancers (rok: 2019, tom: 11, strony: E326), Wydawca: MDPI
    Status:
    Published
    DOI:
    10.3390/cancers11030326 - link to the publication
  4. miRNAs in Melanoma: Tumor Suppressors and Oncogenes with Prognostic Potential.
    Authors:
    Wozniak M, Mielczarek A, Czyz M.
    Academic press:
    Current Medicinal Chemistry (rok: 2016, tom: 23 (28), strony: 3136-3153), Wydawca: Bentham Science Publishers
    Status:
    Published
    DOI:
    brak - link to the publication
  5. Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic Plasticity
    Authors:
    Mariusz L. Hartman, Malgorzata Sztiller-Sikorska, Anna Gajos-Michniewicz and Malgorzata Czyz
    Academic press:
    Cells (rok: 2020, tom: 9, strony: 142), Wydawca: MDPI
    Status:
    Published
    DOI:
    10.3390/cells9010142 - link to the publication
  6. Inhibitors of HSP90 in melanoma
    Authors:
    Aleksandra Mielczarek-Lewandowska, Mariusz L. Hartman, Malgorzata Czyz
    Academic press:
    Apoptosis (rok: 2020, tom: 25, strony: 46019), Wydawca: Springer
    Status:
    Published
    DOI:
    10.1007/s10495-019-01577-1 - link to the publication
  7. Plasticity of Drug-Naïve and Vemurafenib- or Trametinib-Resistant Melanoma Cells in Execution of Differentiation/Pigmentation Program
    Authors:
    Czyz M, Sztiller-Sikorska M, Gajos-Michniewicz A, Osrodek M, Hartman ML
    Academic press:
    Journal of Oncology (rok: 2019, tom: 2019, strony: 1697913), Wydawca: Hindawi
    Status:
    Published
    DOI:
    10.1155/2019/1697913 - link to the publication
  8. Whole-exome sequencing reveals novel genetic variants associated with diverse phenotypes of melanoma cells
    Authors:
    Hartman ML, Sztiller-Sikorska M, Czyz M
    Academic press:
    Molecular Carcinogenesis (rok: 2019, tom: 58, strony: 588-602), Wydawca: Wiley
    Status:
    Published
    DOI:
    10.1002/mc.22953 - link to the publication
  9. Inhibitors of HSP90 in melanoma
    Authors:
    Aleksandra Mielczarek-Lewandowska, Mariusz L. Hartman, Malgorzata Czyz
    Academic press:
    Apoptosis (rok: 2020, tom: 25, strony: 46019), Wydawca: Springer
    Status:
    Published
    DOI:
    10.1007/s10495-019-01577-1 - link to the publication
  10. 17-Aminogeldanamycin Inhibits Constitutive Nuclear Factor-Kappa B (NF-κB) Activity in Patient-Derived Melanoma Cell Lines
    Authors:
    Hartman ML, Rogut M, Mielczarek-Lewandowska A, Wozniak M, Czyz M
    Academic press:
    International Journal of Molecular Sciences (rok: 2020, tom: 21, strony: 3749), Wydawca: MDPI
    Status:
    Published
    DOI:
    10.3390/ijms21113749 - link to the publication
  11. 17-Aminogeldanamycin selectively diminishes IRE1α-XBP1s pathway activity and cooperatively induces apoptosis with MEK1/2 and BRAFV600E inhibitors in melanoma cells of different genetic subtypes.
    Authors:
    Mielczarek-Lewandowska A, Sztiller-Sikorska M, Osrodek M, Czyz M, Hartman ML
    Academic press:
    Apoptosis (rok: 2019, tom: 24, strony: 596-611), Wydawca: Springer
    Status:
    Published
    DOI:
    10.1007/s10495-019-01542-y - link to the publication
  12. 17-Aminogeldanamycin Inhibits Constitutive Nuclear Factor-Kappa B (NF-κB) Activity in Patient-Derived Melanoma Cell Lines
    Authors:
    Hartman ML, Rogut M, Mielczarek-Lewandowska A, Wozniak M, Czyz M
    Academic press:
    International Journal of Molecular Sciences (rok: 2020, tom: 21, strony: 3749), Wydawca: MDPI
    Status:
    Published
    DOI:
    10.3390/ijms21113749 - link to the publication
  13. Vemurafenib and trametinib reduce expression of CTGF and IL-8 in V600EBRAF melanoma cells
    Authors:
    Hartman ML, Rozanski M, Osrodek M, Zalesna I, Czyz M.
    Academic press:
    Laboratory Investigation (rok: 2017, tom: 97(2), strony: 217-227), Wydawca: Nature Publishing Group
    Status:
    Published
    DOI:
    10.1038/labinvest.2016.140. - link to the publication
  14. HGF/c-MET Signaling in Melanocytes and Melanoma
    Authors:
    Czyz M
    Academic press:
    International Journal of Molecular Sciences (rok: 2018, tom: 19 (12), strony: E3844), Wydawca: MDPI
    Status:
    Published
    DOI:
    10.3390/ijms19123844 - link to the publication
  15. TYRP1 mRNA level is stable and MITF-M-independent in drug-naïve and vemurafenibresistant melanoma cells
    Authors:
    Hartman ML Czyz M
    Academic press:
    Archives of Dermatological Research (rok: 2020, tom: 12, strony: 385-392), Wydawca: Springer
    Status:
    Published
    DOI:
    10.1007/s00403-019-01995-w - link to the publication
  16. Exogenous growth factors bFGF, EGF and HGF do not influence viability and phenotype of V600EBRAF melanoma cells and their response to vemurafenib and trametinib in vitro
    Authors:
    Zalesna I, Osrodek M, Hartman ML, Rozanski M, Sztiller-Sikorska M, Niewinna K, Nejc D, Czyz M
    Academic press:
    PlosOne (rok: 2017, tom: 12 (8), strony: e0183498), Wydawca: PLOS
    Status:
    Published
    DOI:
    10.1371/journal.pone - link to the publication
  17. Physiologically Relevant Oxygen Concentration (6% O2) as an Important Component of the Microenvironment Impacting Melanoma Phenotype and Melanoma Response to Targeted Therapeutics In Vitro
    Authors:
    Osrodek M, Hartman ML, Czyz M
    Academic press:
    International Journal of Molecular Sciences (rok: 2019, tom: 20, strony: E4203), Wydawca: MDPI
    Status:
    Published
    DOI:
    10.3390/ijms20174203 - link to the publication
  18. TYRP1 mRNA level is stable and MITF-M-independent in drug-naïve and vemurafenibresistant melanoma cells
    Authors:
    Hartman ML Czyz M
    Academic press:
    Archives of Dermatological Research (rok: 2020, tom: 12, strony: 385-392), Wydawca: Springer
    Status:
    Published
    DOI:
    10.1007/s00403-019-01995-w - link to the publication

O Narodowym Centrum Nauki

Finansowanie nauki

Współpraca zagraniczna

Centrum prasowe

Deklaracja dostępności
Przetwarzanie danych osobowych
Polityka cookies

Partnerzy